ARCOSA INC (ACA) Fundamental Analysis & Valuation
NYSE:ACA • US0396531008
Current stock price
105.3 USD
+0.06 (+0.06%)
Last:
This ACA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. ACA Profitability Analysis
1.1 Basic Checks
- In the past year ACA was profitable.
- In the past year ACA had a positive cash flow from operations.
- ACA had positive earnings in 4 of the past 5 years.
- ACA had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- ACA has a Return On Assets (2.94%) which is in line with its industry peers.
- Looking at the Return On Equity, with a value of 5.75%, ACA is in line with its industry, outperforming 46.43% of the companies in the same industry.
- With a Return On Invested Capital value of 4.99%, ACA perfoms like the industry average, outperforming 44.64% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for ACA is significantly below the industry average of 17.30%.
- The last Return On Invested Capital (4.99%) for ACA is above the 3 year average (3.99%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.94% | ||
| ROE | 5.75% | ||
| ROIC | 4.99% |
ROA(3y)4.56%
ROA(5y)3.97%
ROE(3y)7.3%
ROE(5y)6.21%
ROIC(3y)3.99%
ROIC(5y)4.04%
1.3 Margins
- ACA has a Profit Margin of 5.25%. This is in the better half of the industry: ACA outperforms 62.50% of its industry peers.
- In the last couple of years the Profit Margin of ACA has declined.
- ACA has a better Operating Margin (10.27%) than 69.64% of its industry peers.
- ACA's Operating Margin has declined in the last couple of years.
- ACA has a Gross Margin of 21.61%. This is in the better half of the industry: ACA outperforms 67.86% of its industry peers.
- ACA's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | 5.25% | ||
| GM | 21.61% |
OM growth 3Y11.96%
OM growth 5Y-2.91%
PM growth 3Y2.37%
PM growth 5Y-10.81%
GM growth 3Y3.69%
GM growth 5Y0.93%
2. ACA Health Analysis
2.1 Basic Checks
- ACA has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- ACA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- ACA has an Altman-Z score of 2.39. This is not the best score and indicates that ACA is in the grey zone with still only limited risk for bankruptcy at the moment.
- The Altman-Z score of ACA (2.39) is comparable to the rest of the industry.
- ACA has a debt to FCF ratio of 5.03. This is a neutral value as ACA would need 5.03 years to pay back of all of its debts.
- ACA's Debt to FCF ratio of 5.03 is fine compared to the rest of the industry. ACA outperforms 62.50% of its industry peers.
- ACA has a Debt/Equity ratio of 0.61. This is a neutral value indicating ACA is somewhat dependend on debt financing.
- With a Debt to Equity ratio value of 0.61, ACA perfoms like the industry average, outperforming 53.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 5.03 | ||
| Altman-Z | 2.39 |
ROIC/WACC0.52
WACC9.65%
2.3 Liquidity
- ACA has a Current Ratio of 2.02. This indicates that ACA is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Current ratio value of 2.02, ACA belongs to the best of the industry, outperforming 89.29% of the companies in the same industry.
- A Quick Ratio of 1.30 indicates that ACA should not have too much problems paying its short term obligations.
- ACA has a better Quick ratio (1.30) than 64.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.3 |
3. ACA Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 48.50% over the past year.
- Measured over the past years, ACA shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.78% on average per year.
EPS 1Y (TTM)48.5%
EPS 3Y26.66%
EPS 5Y12.78%
EPS Q2Q%150%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.58%
3.2 Future
- Based on estimates for the next years, ACA will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.17% on average per year.
- ACA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.28% yearly.
EPS Next Y9.06%
EPS Next 2Y11.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year5.18%
Revenue Next 2Y5.28%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. ACA Valuation Analysis
4.1 Price/Earnings Ratio
- ACA is valuated rather expensively with a Price/Earnings ratio of 23.56.
- ACA's Price/Earnings ratio is a bit cheaper when compared to the industry. ACA is cheaper than 78.57% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 26.11. ACA is around the same levels.
- ACA is valuated rather expensively with a Price/Forward Earnings ratio of 21.60.
- ACA's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ACA is cheaper than 75.00% of the companies in the same industry.
- ACA's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.12.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.56 | ||
| Fwd PE | 21.6 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, ACA is valued a bit cheaper than the industry average as 76.79% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, ACA is valued cheaper than 83.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.41 | ||
| EV/EBITDA | 12.61 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)2.6
PEG (5Y)1.84
EPS Next 2Y11.17%
EPS Next 3YN/A
5. ACA Dividend Analysis
5.1 Amount
- ACA has a yearly dividend return of 0.19%, which is pretty low.
- ACA's Dividend Yield is rather good when compared to the industry average which is at 0.14. ACA pays more dividend than 80.36% of the companies in the same industry.
- With a Dividend Yield of 0.19, ACA pays less dividend than the S&P500 average, which is at 1.91.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.19% |
5.2 History
- The dividend of ACA decreases each year by -0.48%.
- ACA has been paying a dividend for over 5 years, so it has already some track record.
- As ACA did not decrease their dividend in the past 5 years, we can say the dividend looks stable.
Dividend Growth(5Y)-0.48%
Div Incr Years0
Div Non Decr Years5
5.3 Sustainability
- 6.66% of the earnings are spent on dividend by ACA. This is a low number and sustainable payout ratio.
DP6.66%
EPS Next 2Y11.17%
EPS Next 3YN/A
ACA Fundamentals: All Metrics, Ratios and Statistics
NYSE:ACA (3/18/2026, 1:46:49 PM)
105.3
+0.06 (+0.06%)
Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryConstruction & Engineering
Earnings (Last)02-26 2026-02-26/amc
Earnings (Next)05-04 2026-05-04
Inst Owners94.27%
Inst Owner Change-3.24%
Ins Owners1.85%
Ins Owner Change2.68%
Market Cap5.16B
Revenue(TTM)N/A
Net Income(TTM)148.60M
Analysts84.44
Price Target125.66 (19.34%)
Short Float %1.88%
Short Ratio3.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.19% |
Yearly Dividend0.2
Dividend Growth(5Y)-0.48%
DP6.66%
Div Incr Years0
Div Non Decr Years5
Ex-Date04-15 2026-04-15 (0.05)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.63%
Min EPS beat(2)15.61%
Max EPS beat(2)17.65%
EPS beat(4)3
Avg EPS beat(4)38.79%
Min EPS beat(4)-40.32%
Max EPS beat(4)162.24%
EPS beat(8)7
Avg EPS beat(8)30.62%
EPS beat(12)11
Avg EPS beat(12)32.12%
EPS beat(16)15
Avg EPS beat(16)40.53%
Revenue beat(2)1
Avg Revenue beat(2)-1.27%
Min Revenue beat(2)-3.72%
Max Revenue beat(2)1.18%
Revenue beat(4)2
Avg Revenue beat(4)-1.29%
Min Revenue beat(4)-4.44%
Max Revenue beat(4)1.83%
Revenue beat(8)4
Avg Revenue beat(8)-0.83%
Revenue beat(12)7
Avg Revenue beat(12)0.53%
Revenue beat(16)11
Avg Revenue beat(16)1.99%
PT rev (1m)-0.48%
PT rev (3m)2.81%
EPS NQ rev (1m)-0.54%
EPS NQ rev (3m)-1.1%
EPS NY rev (1m)-0.12%
EPS NY rev (3m)0.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.46%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.07%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.56 | ||
| Fwd PE | 21.6 | ||
| P/S | 1.82 | ||
| P/FCF | 16.41 | ||
| P/OCF | 11 | ||
| P/B | 2 | ||
| P/tB | 5.62 | ||
| EV/EBITDA | 12.61 |
EPS(TTM)4.47
EY4.25%
EPS(NY)4.88
Fwd EY4.63%
FCF(TTM)6.42
FCFY6.09%
OCF(TTM)9.57
OCFY9.09%
SpS57.77
BVpS52.71
TBVpS18.73
PEG (NY)2.6
PEG (5Y)1.84
Graham Number72.81
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.94% | ||
| ROE | 5.75% | ||
| ROCE | 6.5% | ||
| ROIC | 4.99% | ||
| ROICexc | 5.24% | ||
| ROICexgc | 8.62% | ||
| OM | 10.27% | ||
| PM (TTM) | 5.25% | ||
| GM | 21.61% | ||
| FCFM | 11.11% |
ROA(3y)4.56%
ROA(5y)3.97%
ROE(3y)7.3%
ROE(5y)6.21%
ROIC(3y)3.99%
ROIC(5y)4.04%
ROICexc(3y)4.17%
ROICexc(5y)4.21%
ROICexgc(3y)7.17%
ROICexgc(5y)7.33%
ROCE(3y)5.21%
ROCE(5y)5.27%
ROICexgc growth 3Y4.01%
ROICexgc growth 5Y-10.09%
ROICexc growth 3Y4.98%
ROICexc growth 5Y-11.63%
OM growth 3Y11.96%
OM growth 5Y-2.91%
PM growth 3Y2.37%
PM growth 5Y-10.81%
GM growth 3Y3.69%
GM growth 5Y0.93%
F-Score5
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 5.03 | ||
| Debt/EBITDA | 3.04 | ||
| Cap/Depr | 68.36% | ||
| Cap/Sales | 5.46% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 90.74% | ||
| Profit Quality | 211.71% | ||
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.3 | ||
| Altman-Z | 2.39 |
F-Score5
WACC9.65%
ROIC/WACC0.52
Cap/Depr(3y)104.81%
Cap/Depr(5y)89.02%
Cap/Sales(3y)7.45%
Cap/Sales(5y)6.15%
Profit Quality(3y)128.08%
Profit Quality(5y)133.99%
High Growth Momentum
Growth
EPS 1Y (TTM)48.5%
EPS 3Y26.66%
EPS 5Y12.78%
EPS Q2Q%150%
EPS Next Y9.06%
EPS Next 2Y11.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.58%
Revenue Next Year5.18%
Revenue Next 2Y5.28%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y48.65%
EBIT growth 3Y20.99%
EBIT growth 5Y5.01%
EBIT Next Year135.6%
EBIT Next 3Y38.61%
EBIT Next 5YN/A
FCF growth 1Y5015.62%
FCF growth 3Y56.55%
FCF growth 5Y2.7%
OCF growth 1Y146.35%
OCF growth 3Y44.47%
OCF growth 5Y6.95%
ARCOSA INC / ACA Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for ARCOSA INC?
ChartMill assigns a fundamental rating of 5 / 10 to ACA.
Can you provide the valuation status for ARCOSA INC?
ChartMill assigns a valuation rating of 4 / 10 to ARCOSA INC (ACA). This can be considered as Fairly Valued.
How profitable is ARCOSA INC (ACA) stock?
ARCOSA INC (ACA) has a profitability rating of 5 / 10.
What is the valuation of ARCOSA INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ARCOSA INC (ACA) is 23.56 and the Price/Book (PB) ratio is 2.
How financially healthy is ARCOSA INC?
The financial health rating of ARCOSA INC (ACA) is 5 / 10.